Collegium Pharmaceutical, Inc. COLL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.5M+500% | $16.96M+35.3% | $31.51M+238% | $11.98M-38.9% | $2.42M-91.3% | ||
| $463K-57.6% | $923K-11.3% | $1.03M+9.2% | $1.14M+19.2% | $1.09M+19.0% | ||
| $10.88M-5.6% | $9.75M+28.4% | $9.81M+34.1% | $10.82M+8.1% | $11.52M+54.2% | ||
| -$968K-79.6% | -$10.07M+0.8% | -$12.13M-38.9% | -$2.91M+17.1% | -$539K+87.8% | ||
| $819K-40.1% | $1.28M-10.4% | $1.34M+11.2% | $1.36M-15.5% | $1.37M-23.2% | ||
| $17.43M+10,155% | -$22.62M— | $20.93M+10,914% | -$15.68M-271% | $170K+104% | ||
| $1.83M+10.3% | $2.86M+216% | $0+100% | $930K+127% | $1.66M+257% | ||
| -$3.83M-127% | $3.05M— | —— | —— | $13.92M+649% | ||
| -$4.15M+76.5% | —— | -$8.11M+87.1% | —— | -$17.67M-2,778% | ||
| -$4.13M-140% | $8.19M+320% | -$21.34M-5,016% | $10.85M-5.8% | $10.27M+5,703% | ||
| -$167K— | -$167K— | —— | —— | $0— | ||
| $55.47M0.0% | —— | —— | —— | $55.47M+60.7% | ||
| $0+100% | -$19K+99.3% | -$19K— | -$358K— | -$786K— | ||
| $57.11M+3.1% | $123.05M+45.4% | $78.44M— | $72.44M+7.5% | $55.4M-10.6% | ||
| $270K-66.2% | $689K+20.9% | $188K-23.0% | $65K-75.9% | $798K+40.5% | ||
| $1.63M+117% | -$20.07M-70.6% | -$30.87M+87.6% | -$2.92M+67.3% | -$9.68M+46.6% | ||
| $7.25M-55.1% | $587.12M+3,536% | $16.15M— | $16.15M-64.8% | $16.15M-64.8% | ||
| $394K-74.6% | $985K+469% | $1.44M+863% | $308K-94.6% | $1.55M-63.1% | ||
| $15.43M+45.7% | $861K+209% | $964K+579% | $428K-92.7% | $10.59M-17.7% | ||
| $0-100% | —— | —— | $7M— | $555K— | ||
| -$21.34M+15.4% | -$21.82M+47.1% | -$14.82M— | -$48.37M+57.6% | -$25.24M+53.4% | ||
| $37.4M+82.6% | $81.16M— | $32.75M+130% | $21.15M+138% | $20.48M+298% | ||
| $22.11M+1.9% | $11.69M-23.2% | $21.53M+21.8% | $13.85M+14.7% | $21.69M+24.2% | ||
| $44K-98.2% | $12.28M+1,877% | $15.49M-0.6% | $29.82M-16.5% | $2.46M+1,320% | ||
| $178K-45.1% | $254K-32.4% | $230K-55.3% | $264K-63.5% | $324K-21.9% | ||
| $819K-40.1% | $1.28M-10.4% | $1.34M+11.2% | $1.36M-15.5% | $1.37M-23.2% | ||
| $55.47M0.0% | —— | —— | —— | $55.47M+60.7% | ||
| $0+100% | -$19K+99.3% | -$19K— | -$358K— | -$786K— | ||
| $463K-57.6% | $923K-11.3% | $1.03M+9.2% | $1.14M+19.2% | $1.09M+19.0% | ||
| -$575K-483% | $8.66M— | $2.43M— | -$8.39M-146% | $150K+102% | ||
| -$4.13M-140% | $8.19M+320% | -$21.34M-5,016% | $10.85M-5.8% | $10.27M+5,703% | ||
| $71K-92.2% | —— | —— | $1.11M— | $909K— | ||
| -$91K-203% | —— | $503K+2,287% | -$30K-36.4% | -$30K-36.4% | ||
| $947K+87.2% | —— | $857K+82.0% | —— | $506K+42.1% | ||
| $7.25M-55.1% | $587.12M+3,536% | $16.15M— | $16.15M-64.8% | $16.15M-64.8% | ||
| $207K— | $5K-89.2% | $190K+311% | $124K+168% | $0-100% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$167K— | -$167K— | —— | —— | $0— | ||
| $0-100% | —— | —— | $7M— | $555K— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $44K-98.2% | $12.28M+1,877% | $15.49M-0.6% | $29.82M-16.5% | $2.46M+1,320% | ||
| $56.84M+4.1% | $122.36M+45.5% | $78.25M— | $72.37M+7.8% | $54.6M-11.0% | ||
| $56.84M+4.1% | $122.36M+45.5% | $78.25M— | $72.37M+7.8% | $54.6M-11.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Collegium Pharmaceutical, Inc. generate?
- Collegium Pharmaceutical, Inc. (COLL) generated $331.0M in operating cash flow over the trailing twelve months.
- What is Collegium Pharmaceutical, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Collegium Pharmaceutical, Inc.'s free cash flow was $329.8M over the trailing twelve months, up 60.3% year over year.
- Where does Collegium Pharmaceutical, Inc.'s cash flow data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
